INmune: IND Application for INKmune for Treatment of Prostate Cancer

  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of INKmune™ to treat metastatic castration-resistant prostate cancer (mCRPC).

https://www.biospace.com/article/releases/inmune-bio-inc-announces-submission-of-investigational-new-drug-ind-application-for-inkmune-to-the-u-s-food-and-drug-administration-for-treatment-of-metastatic-castration-resistant-prostate-cancer/